Best Researcher Award
April Schultz
Sanford Children’s Genomic Medicine Consortium, United States
April Schultz is a researcher whose scholarly work focuses on genetics, genomics, and clinical pharmacogenomics, particularly within pediatric precision medicine. Her publications emphasize the implementation of genomic testing, clinical decision support, and personalized therapeutic strategies that improve medication safety and effectiveness. With a documented Scopus profile containing 23 indexed publications, 271 citations, and an h-index of 9, her research demonstrates sustained engagement with translational genomic medicine and interdisciplinary collaboration.[1]
Abstract
April Schultz has contributed to the advancement of pharmacogenomics through studies integrating genomic information into clinical practice. Her work examines medication response, implementation of genomic testing, and healthcare decision support, with particular emphasis on pediatric populations and personalized medicine. These investigations contribute to evidence-based genomic healthcare and collaborative translational research.[2]
Keywords
- Genetics
- Genomics
- Pharmacogenomics
- Precision Medicine
- Clinical Decision Support
Introduction
Modern genomic medicine increasingly relies on multidisciplinary collaboration to translate genetic discoveries into clinical care. Schultz’s research reflects this transition by evaluating pharmacogenetic implementation, genotype-guided prescribing, and healthcare system integration. Her publications address practical applications of genomic evidence while supporting personalized therapeutic approaches across healthcare environments.[3]
Research Profile
The research profile demonstrates consistent activity in genetics and genomics with measurable scholarly impact. Publications focus on pharmacogenetic implementation, medication optimization, antidepressant therapy, statin-associated adverse effects, and pediatric genomic medicine. Collaborative research across institutions highlights practical translation of genomic discoveries into patient care while supporting precision medicine initiatives.[1]
Research Contributions
Schultz has contributed to investigations evaluating CYP2C19 and CYP2D6-guided antidepressant prescribing, automated clinical decision support for clopidogrel therapy, pharmacogenetic implementation in rural health systems, and genomic consortium development. These studies strengthen evidence supporting genomic integration into routine healthcare and encourage broader adoption of precision medicine technologies.[2]
Publications
- Sanford Children’s Genomic Medicine Consortium shows interinstitutional progression of pediatric pharmacogenomic programs (2026).
- Genotype influences antidepressant discontinuation in a pre-emptive pharmacogenetic testing population (2026).
- Evaluation of pharmacogenetic automated clinical decision support for clopidogrel (2024).
- Incidence of statin-associated muscle symptoms in patients with RYR1 or CACNA1S variants (2024).
- Implementation of CYP2C19 and CYP2D6 genotyping to guide antidepressant use (2024).
Research Impact
The available bibliometric indicators indicate meaningful academic influence within pharmacogenomics and clinical genomics. Citation activity, interdisciplinary collaboration, and publication in peer-reviewed journals demonstrate ongoing engagement with precision medicine research. These outputs contribute to improving genomic implementation strategies and healthcare quality through evidence-based clinical practice.[4]
Award Suitability
Based on documented scholarly publications, citation metrics, and sustained contributions to genetics and genomics, April Schultz demonstrates qualifications consistent with consideration for the Best Researcher Award. Her work reflects scientific rigor, collaborative research, and practical application of genomic medicine while maintaining an evidence-driven research portfolio.[5]
Conclusion
April Schultz’s academic profile represents an active contribution to pharmacogenomics and precision medicine through clinically relevant genomic research. Continued publication activity and interdisciplinary collaboration position her work as a valuable contribution to advancing personalized healthcare and genomic implementation.
External Links
References
- Elsevier. (n.d.). Scopus author details: April Schultz, Author ID 57210791238.
https://www.scopus.com/authid/detail.uri?authorId=57210791238
- Schultz A., et al. (2026). Sanford Children’s Genomic Medicine Consortium shows interinstitutional progression of pediatric pharmacogenomic programs.
https://doi.org/10.1016/j.japhpi.2026.100120
- Schultz A., et al. (2026). Genotype influences antidepressant discontinuation in a pre-emptive pharmacogenetic testing population.
https://doi.org/10.1038/s41397-026-00416-2
- Schultz A., et al. (2024). Evaluation of pharmacogenetic automated clinical decision support for clopidogrel.
https://doi.org/10.1080/14622416.2024.2394014
- Schultz A., et al. (2024). Implementation of CYP2C19 and CYP2D6 genotyping to guide antidepressant use in a large rural health system.
https://doi.org/10.1093/ajhp/zxae083